Research

Energy balance

Older patients were mostly underrepresented in clinical trials of GLP-1 receptor agonists and SGLT2 inhibitors.

Clinical guidelines may need to consider the lack of data on older patients.

StrongRefutesmedium confidence
Über 75-Jährige waren meist unterrepräsentiert.
Svea Stüdemann et al. · Diabetes aktuell · 2025

Why this rating

Based on the analysis of multiple studies.

Source

Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?

Svea Stüdemann et al. · Diabetes aktuell · 2025

DOI 10.1055/a-2588-6338

other · n=104
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →